Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs. 2017 06; 35(3):334-344.

View in: PubMed

subject areas

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Carboplatin
Cell Count
Disease-Free Survival
Etoposide
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Neoplastic Cells, Circulating
Peptides, Cyclic
Prognosis
Receptors, CXCR4
Small Cell Lung Carcinoma

authors with profiles

Ravi Salgia